Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2014

Atenolol versus losartan in children and young adults with
Marfan's syndrome
A C. Braverman
Washington University School of Medicine in St. Louis

A M. Sharkey
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Braverman, A C.; Sharkey, A M.; and et al, ,"Atenolol versus losartan in children and young adults with
Marfan's syndrome." The New England Journal of Medicine. 371,22. 2061-71. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/3556

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

new england
journal of medicine
The

established in 1812

november 27, 2014

vol. 371

no. 22

Atenolol versus Losartan in Children and Young Adults
with Marfan’s Syndrome
R.V. Lacro, H.C. Dietz, L.A. Sleeper, A.T. Yetman, T.J. Bradley, S.D. Colan, G.D. Pearson, E.S. Selamet Tierney,
J.C. Levine, A.M. Atz, D.W. Benson, A.C. Braverman, S. Chen, J. De Backer, B.D. Gelb, P.D. Grossfeld, G.L. Klein,
W.W. Lai, A. Liou, B.L. Loeys, L.W. Markham, A.K. Olson, S.M. Paridon, V.L. Pemberton, M.E. Pierpont, R.E. Pyeritz,
E. Radojewski, M.J. Roman, A.M. Sharkey, M.P. Stylianou, S. Burns Wechsler, L.T. Young, and L. Mahony,
for the Pediatric Heart Network Investigators*

A BS T R AC T
BACKGROUND

Aortic-root dissection is the leading cause of death in Marfan’s syndrome. Studies
suggest that with regard to slowing aortic-root enlargement, losartan may be more
effective than beta-blockers, the current standard therapy in most centers.
METHODS

We conducted a randomized trial comparing losartan with atenolol in children and
young adults with Marfan’s syndrome. The primary outcome was the rate of aorticroot enlargement, expressed as the change in the maximum aortic-root-diameter
z score indexed to body-surface area (hereafter, aortic-root z score) over a 3-year
period. Secondary outcomes included the rate of change in the absolute diameter of
the aortic root; the rate of change in aortic regurgitation; the time to aortic dissection,
aortic-root surgery, or death; somatic growth; and the incidence of adverse events.
RESULTS
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From January 2007 through February 2011, a total of 21 clinical centers enrolled
608 participants, 6 months to 25 years of age (mean [±SD] age, 11.5±6.5 years in
the atenolol group and 11.0±6.2 years in the losartan group), who had an aorticroot z score greater than 3.0. The baseline-adjusted rate of change (±SE) in the
aortic-root z score did not differ significantly between the atenolol group and the
losartan group (−0.139±0.013 and −0.107±0.013 standard-deviation units per year,
respectively; P = 0.08). Both slopes were significantly less than zero, indicating a
decrease in the degree of aortic-root dilatation relative to body-surface area with
either treatment. The 3-year rates of aortic-root surgery, aortic dissection, death,
and a composite of these events did not differ significantly between the two treatment groups.
CONCLUSIONS

Among children and young adults with Marfan’s syndrome who were randomly assigned to losartan or atenolol, we found no significant difference in the rate of aorticroot dilatation between the two treatment groups over a 3-year period. (Funded by
the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number,
NCT00429364.)
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arfan’s syndrome is an autosomal dominant disorder of connective
tissue affecting approximately 1 in
5000 people.1 Cardiovascular disease, mainly
progressive aortic-root dilatation and dissection,
is the leading cause of death in Marfan’s syndrome. After an open-label, randomized trial
comparing propranolol with no therapy, published in 1994, showed a reduced rate of aortic
enlargement among treated patients, beta-adrenergic receptor antagonists (beta-blockers) became
the mainstay of medical management.2 Current
management includes serial cardiac imaging, exercise restriction, administration of beta-blockers,
and elective aortic-root replacement.3 Although
early diagnosis and refined medical and surgical
treatment have improved survival, patients with
Marfan’s syndrome continue to have high rates
of cardiovascular disease and early death.
Marfan’s syndrome is caused by mutations in
FBN1,4 the gene that encodes fibrillin-1, a component of extracellular microfibrils. Fibrillin-1
binds the latent complex of the cytokine transforming growth factor β (TGF-β) and regulates
its activation and signaling. Studies in a mouse
model of Marfan’s syndrome showed that a deficiency of fibrillin-1 was associated with excessive
signaling by TGF-β. Excessive TGF-β activation
and signaling are currently thought to contribute to the pleiotropic manifestations of Marfan’s
syndrome, including aortic-root dilatation and
dissection.5,6
The angiotensin II type 1–receptor blocker
(ARB) losartan has been shown to attenuate
TGF-β signaling in some disease states, such as
chronic renal failure, presumably by decreasing
the expression of TGF-β ligands,6,7 receptors,8
and activators.9 The rate of aortic-root growth
among mice with Marfan’s syndrome treated
with losartan was similar to that among wildtype mice and was significantly less than that
among untreated littermates with Marfan’s syndrome.10 Although the beta-blocker propranolol
also reduced the rate of aortic-root growth
among mice with Marfan’s syndrome, this effect
was much less pronounced than that seen with
losartan. Losartan therapy in mice with Marfan’s
syndrome prevented elastic-fiber fragmentation
and therefore preserved aortic-wall architecture.10
Losartan also decreased the rate of aortic-root
dilatation in two small series of children with
Marfan’s syndrome.11,12 The goal of the present
2062

n engl j med 371;22

of

m e dic i n e

trial was to determine whether the rate of aorticroot enlargement during treatment with losartan
differs from the rate during treatment with atenolol among patients with Marfan’s syndrome
and a dilated aortic root.

ME THODS
STUDY DESIGN

The study design has been published previously.13 The trial was designed and performed by the
Marfan Trial Subcommittee of the Pediatric
Heart Network (see the Supplementary Appendix, available with the full text of this article at
NEJM.org). The protocol (available at NEJM.org)
was approved by the institutional review board or
ethics committee at each study center. The data
were collected by center investigators and analyzed at the data coordinating center (New En
gland Research Institutes). The lead statistician
(the third author) vouches for the accuracy of the
data and analyses, and all the authors vouch for
the fidelity of this report to the trial protocol.
The trial was sponsored by the National
Heart, Lung, and Blood Institute, with additional
financial support provided by the Food and Drug
Administration (FDA) Office of Orphan Products
Development and the Marfan Foundation. Merck
and Teva Canada provided losartan and atenolol,
respectively, but these companies had no role in
the design or conduct of the trial, data collection
or analysis, or the writing of the manuscript or
the decision to submit it for publication.
PARTICIPANTS

Inclusion criteria were an age of 6 months to 25
years, a diagnosis of Marfan’s syndrome according to the original Ghent criteria (Table S1 in the
Supplementary Appendix),14 and a z score for the
maximum aortic-root diameter indexed to bodysurface area (hereafter, aortic-root z score) greater than 3.0 (as determined by measurement at the
local study site). Exclusion criteria were previous
or impending aortic surgery; an aortic-root diameter greater than 5 cm; a history of aortic dissection; a diagnosis of the Loeys–Dietz syndrome15
or the Shprintzen–Goldberg syndrome16; therapeutic rather than prophylactic use of an angiotensin-converting–enzyme inhibitor, beta-blocker,
or calcium-channel blocker; prior adverse effects
related to treatment with ARB or beta-blocker
therapy or a contraindication to such treatment;
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and an inability to complete study procedures.
The primary outcome was the rate of aorticWritten informed consent was obtained from root enlargement, expressed as the annual change
each participant or the participant’s parent or in the aortic-root z score, measured by means of
guardian.
echocardiography as previously described,19 over
the 3-year period after randomization. Secondary
STUDY PROCEDURES
outcomes included the rate of change in the
Participants were assigned to atenolol or losartan absolute diameter of the aortic root; the rate of
in a 1:1 ratio with the use of randomly permuted change in the z score and the absolute diameter
blocks stratified according to age (young adults of the ascending aorta and the aortic annulus;
[defined as male participants 16 to 25 years of the rate of change in aortic regurgitation; time
age and female participants 15 to 25 years of age] to aortic dissection, aortic-root surgery, or death
vs. children [male participants younger than 16 (clinical outcomes); the rate of change in anthroyears of age and female participants younger pometric outcomes (height, weight, body-mass
than 15 years of age])17 and a baseline aortic-root index, ratio of upper to lower body segment,
z score of less than 4.5 versus a z score of 4.5 or and ratio of arm span to height); and the incigreater. Dynamic allocation was performed with- dence of adverse events and participant-reported
in each center.18
symptoms.
Atenolol (at an initial dose of 0.5 mg per kilogram of body weight) was increased on the basis STATISTICAL ANALYSIS
of the hemodynamic response up to a maximum We designed the trial to have, with an alpha level
dose of 4.0 mg per kilogram per day (not to ex- of 0.05, 85% power to detect a treatment differceed a total dose of 250 mg), with a goal of a ence of 0.194 standard-deviation units (z score
20% or greater decrease in the mean heart rate units) per year13 in the aortic-root z score, after
as measured on a 24-hour recording.13 Losartan adjustment for treatment crossover, an assumed
(at an initial dose of 0.4 mg per kilogram) was withdrawal rate of up to 20%, and three interim
adjusted on the basis of body weight up to a analyses. The resulting target sample was 604
maximum dose of 1.4 mg per kilogram per day participants.
(not to exceed a total dose of 100 mg), as recomThe primary analysis was based on the intenmended by the FDA.13
tion-to-treat principle. Secondary analyses were
Study personnel supervising the dose adjust- performed with the use of multiple imputation
ments were aware of the treatment assignments. for missing data, as well as with the exclusion of
All other persons, including participants, fami- 36 participants who were identified after randomlies, and other caregivers, were unaware of the ization as having a major eligibility violation,
treatment assignments. Losartan was provided and with adjustment for status with respect to a
by the manufacturer as unmarked white tablets. history of an endocrine disorder, because the
No unmarked tablets were available for atenolol, prevalence of this baseline characteristic was
which was provided by the manufacturer as unequal in the two treatment groups. A nominal
white tablets that retained the appearance of the P value of less than 0.0453 was required for the
commercially available generic agent, so partici- two-sided analysis of the primary outcome at the
pants and family members may have determined completion of the trial because three interim
the study-drug assignment. Echocardiographic analyses were performed. Adjustments were not
core laboratory readers were unaware of both the made to the significance levels of hypothesis
treatment assignment and the study visit number. tests for secondary trial outcomes.
Echocardiographic and anthropometric outFOLLOW-UP AND OUTCOMES
comes were modeled with linear regression with
Study visits occurred at baseline and at 6, 12, 24, the use of mixed effects to account for the lonand 36 months after randomization. Echocardio- gitudinal design,20 with the use of compound
grams were obtained at each study visit and were symmetry and unstructured covariance strucinterpreted in a core laboratory. Adherence to tures, respectively. The baseline-adjusted rates of
the treatment regimen was assessed according change in the two treatment groups were comto the number of tablets or amount of liquid in pared with the use of a test of the treatment-bythe medication bottles that were returned.
time interaction effect. Linear regression was
n engl j med 371;22
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used to examine the relationship between heart
rate and prescribed dose. The time to clinical
events according to treatment group and according to subgroup for all the participants was
compared with the use of a log-rank test, with
event rates estimated according to the Kaplan–
Meier method. The incidence rates of adverse
events in the two treatment groups were compared with the use of Poisson regression. Treatment-group comparisons of blood pressure, heart
rate, and safety-related laboratory variables were
performed with the use of Student’s t-test or a
Wilcoxon rank-sum test, and treatment-adherence rates and proportions of participants with
each reported drug reaction were compared with
the use of Fisher’s exact test.
The prespecified subgroups defined at baseline were young adults versus children, age as a
continuous variable, aortic-root z score (<4.5 vs.
≥4.5), and previous use of a beta-blocker (yes vs.
no). A differential treatment effect according to
prespecified subgroup was identified by an interaction test (subgroup by treatment by time) in
the longitudinal regression model for the echocardiographic and anthropometric outcomes and
in a Cox proportional-hazards regression model
for clinical outcomes.
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the Supplementary Appendix). The mean absolute doses for young adults were 151±75 mg of
atenolol per day and 85±14 mg of losartan per day.
The proportion of patients who returned at least
60% of medication bottles did not differ significantly between the atenolol group and the losartan group (65% and 64%, respectively; P = 0.86).
On the basis of the amount of medication in the
bottles returned, we estimated that 71% of the
participants took at least 80% of the dispensed
dose (73% of the participants in the atenolol
group and 69% in the losartan group, P = 0.30).
BLOOD-PRESSURE AND HEART-RATE EFFECTS

There were no significant differences between the
two treatment groups in baseline blood pressure
(Table S3 in the Supplementary Appendix). At
3 years, there was a small but significant difference
in the mean diastolic pressure (54±8 mm Hg in
the atenolol group vs. 56±8 mm Hg in the losartan group, P = 0.04) but no significant differences
in the systolic pressure or mean blood pressure
(Table S3 in the Supplementary Appendix).
As expected, the resting and average 24-hour
heart rates were significantly lower at all study
visits in the atenolol group than in the losartan
group (Table S3 in the Supplementary Appendix).
Among children, higher prescribed doses of aten
olol were significantly associated with higher
R E SULT S
resting and average 24-hour heart rates, suggestSTUDY PARTICIPANTS
ing a relative lack of heart-rate responsiveness in
From January 2007 through February 2011, we some participants during the dose-adjustment
enrolled 608 participants at 21 clinical centers; process (Fig. S1 in the Supplementary Appendix).
303 participants were randomly assigned to atenolol and 305 to losartan. The numbers of patients AORTIC-GROWTH OUTCOMES
who were screened, randomly assigned to a treat- The baseline-adjusted annual rate of change
ment group, and included in the analysis of the (±SE) in the aortic-root z score did not differ sigprimary outcome are shown in Figure 1. Baseline nificantly between the atenolol group and the
clinical and echocardiographic characteristics losartan group (−0.139±0.013 and −0.107±0.013
were similar between the atenolol group and the standard-deviation units per year, respectively;
losartan group, except for the incidence of endo- P = 0.08) (Fig. 2A and Table 2). Both slopes were
crine disorders (2% vs. 0%, P = 0.007) (Table 1).19,21 significantly less than zero, indicating a decrease
There was no significant difference in the with- in the aortic-root z score in the two treatment
drawal rate (11% in each group) or in the median groups. There was insufficient evidence to detime from randomization to withdrawal (2.3 years clare a differential treatment effect according to
in the atenolol group and 1.9 years in the losar- any prespecified subgroup analyses (Fig. S2 and
tan group, P = 0.47).
S3 in the Supplementary Appendix), including
age as a continuous variable (P = 0.38 for interacPRESCRIBED DOSE AND ADHERENCE
tion) and an alternative definition of young adult
The mean dose of atenolol was 2.7±1.1 mg per versus child13 that was based on attainment of
kilogram per day, and the mean dose of losartan maximal height (P = 0.38 for interaction).
was 1.3±0.2 mg per kilogram per day (Table S2 in
A younger age at baseline was associated with
2064

n engl j med 371;22

nejm.org

november 27, 2014

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on December 23, 2014. For personal use only. No other uses without permission.
Copyright © 2014 Massachusetts Medical Society. All rights reserved.

Atenolol vs. Losartan in Marfan’s Syndrome

1367 Patients underwent medical-record
review
433 Were ineligible for screening
233 Declined screening

701 Were assessed for eligibility

43 Were eligible but did not undergo
randomization
22 Declined to participate
20 Were ineligible on the basis of
echocardiographic or laboratory results
1 Withdrew consent
50 Were ineligible
38 Did not meet Ghent criteria
12 Had Loeys–Dietz syndrome or
Shprintzen–Goldberg syndrome

608 Underwent randomization

303 Were assigned to atenolol

305 Were assigned to losartan

33 Withdrew from trial
18 Underwent surgery
1 Died
5 Withdrew consent
2 Were withdrawn by
physician
6 Were lost to follow-up
1 Had other reason

32 Withdrew from trial
10 Underwent surgery
11 Withdrew consent
4 Were withdrawn by
physician
5 Were lost to follow-up
2 Had other reason

271 Remained in trial
253 Continued taking study drug
18 Discontinued study drug
2 Received open-label atenolol
1 Received open-label carvedilol
2 Received open-label losartan
13 Did not take beta-blocker or
ARB

272 Remained in trial
264 Continued taking study drug
8 Discontinued study drug
3 Received open-label atenolol
1 Received open-label losartan
4 Did not take beta-blocker or
ARB

268 Were followed for 3 yr

267 Were followed for 3 yr

Figure 1. Screening, Randomization, and Follow-up.
The most common exclusion criterion during the medical-record review (71% of records reviewed) was an aorticroot-diameter z score of less than 3.0. Among the 543 participants who remained in the trial, data for the primary
end point at 3 years were available for all but 11, who had unacceptable or missing echocardiograms (5 participants
in the atenolol group and 6 in the losartan group). In addition, 3 participants withdrew late from the study (2 partic
ipants in the atenolol group because of aortic-root surgery and 1 in the losartan group because of unplanned pregnancy); the echocardiograms obtained at the time of withdrawal for these 3 participants served as the 3 year measurements, yielding a total of 535 participants with data for the primary end point at 3 years (268 participants in the
atenolol group and 267 in the losartan group). ARB denotes angiotensin II–receptor blocker.
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Table 1. Demographic and Clinical Characteristics at Baseline.*
Characteristic

Atenolol
(N = 303)

Losartan
(N = 305)

Age — yr

11.5±6.5

11.0±6.2

Young adult — no. (%)†

76 (25)

75 (25)

180 (59)

186 (61)

White

266 (88)

260 (85)

Black

21 (7)

25 (8)

Asian

6 (2)

10 (3)

Male sex — no. (%)
Race — no. (%)‡

Other

10 (3)

Hispanic — no./total no. (%)‡

10 (3)

36/302 (12)

46/305 (15)

93 (31)

88 (29)

Presence of causal FBN1 mutation — no. (%)
Yes
No
Unknown
Family history of Marfan’s syndrome — no./total no. (%)

9 (3)

15 (5)

201 (66)

202 (66)

180/295 (61)

181/290 (62)

Echocardiographic findings§
Maximum aortic-root diameter — cm

3.4±0.7

3.4±0.7

4.0

4.0

Maximum aortic-root-diameter z score
Median
Interquartile range

3.5–4.8

≥4.5 — no./total no. (%)

106/303 (35)

3.3–5.0
114/304 (38)

Medical history — no. (%)
Cardiac surgery

6 (2)

6 (2)

Cardiovascular disorder¶

39 (13)

36 (12)

Prior use of beta-blocker

173 (57)

171 (56)

Endocrine disorder‖

7 (2)

0

Neurodevelopmental disorder**

56 (18)

61 (20)

Psychiatric disorder††

23 (8)

16 (5)

* Data are adapted from Lacro et al.21 Plus–minus values are means ±SD. The demographic and clinical characteristics
did not differ significantly between the two treatment groups (P>0.20 for all comparisons), with the exception of a history of an endocrine disorder (P = 0.007).
† Young adults were defined as male participants who were 16 to 25 years of age and female participants who were 15
to 25 years of age.
‡ Race or ethnic group was reported by the participant or a family member at the time of enrollment.
§ Data are based on readings at a central echocardiographic laboratory. Echocardiographic data were missing for one
participant in the losartan group because of an unreadable echocardiogram.
¶ Cardiovascular disorder was defined by exercise intolerance; syncope; arrhythmia, hypertension, or hypotension requiring
therapy; chest pain; shortness of breath; or other cardiovascular conditions.
‖ Endocrine disorder was defined by either the use of hormone therapy to limit growth or delayed puberty.
** Neurodevelopmental disorder was defined as attention deficit–hyperactivity disorder requiring therapy, developmental
delay requiring therapy, learning disability requiring services, or other neurodevelopmental conditions.
†† Psychiatric disorder was defined as depression requiring therapy, anxiety, or other psychiatric conditions.

a greater decrease in the aortic-root z score over
time in the atenolol group (P<0.001) and in the
losartan group (P = 0.002), without a significant
difference between the treatment groups (P = 0.38
2066
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for interaction) (Table S4 in the Supplementary
Appendix). The annual change in the aortic-root
z score in children and young adults did not vary
according to the prescribed dose (P = 0.51 for
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interaction in the atenolol group; P = 0.78 for
interaction in the losartan group) (Table S5 in
the Supplementary Appendix).
The average annual rate of change in the absolute diameter of the aortic root was similar in
the two treatment groups (Table 2 and Fig. 2B).
There were small but significant differences favoring atenolol in the average annual change in the
absolute diameter and z score for the aortic annulus, but there were no significant differences
in the diameter or z score for the ascending
aorta (Table 2). The results of the secondary
analyses of the aortic-root z score and data on the
anthropometric outcomes are shown in Tables
S6, S7, and S8 in the Supplementary Appendix.

Atenolol

P=0.08
4.4

4.2

4.0

3.8

3.6
0.0

0

1

2

3

Years since Randomization
No. at Risk
Atenolol
Losartan

303
303

286
293

282
279

268
267

B
3.7

Maximum Aortic-Root Diameter (cm)

ADVERSE CLINICAL OUTCOMES

The 3-year rates of aortic-root surgery, aortic dissection, death, and a composite of these events
did not differ significantly between the two treatment groups (Fig. 3 and Table 2), nor did the
treatment effect depend on subgroup. Additional
clinical information regarding participants with
these events is provided in the Supplementary
Appendix. In an analysis that combined the two
treatment groups, the 3-year rate of aortic-root
surgery was approximately 2 times as high among
young adults as among children (8.5% vs. 3.8%,
P = 0.03) and approximately 15 times as high
among participants with a baseline aortic-root
z score of 4.5 or greater as among those with a
z score of less than 4.5 (12.2% vs. 0.8%, P<0.001).

Losartan

A

Aortic-Root z Score

Figure 2. Change in Aortic-Root z Score and AorticRoot Diameter, According to Treatment Group.
The aortic-root z score is the z score for the maximum
diameter of the aortic root, indexed to body-surface
area. Panel A shows the baseline-adjusted rate of change
in the aortic-root z score over the 3-year period (solid
lines), with 95% confidence intervals (dashed lines) for
the pointwise comparison. Panel B shows the baselineadjusted rate of change in the maximum diameter of
the aortic root over the 3-year period (solid lines), with
95% confidence intervals (dashed lines) for the pointwise comparison.

P=0.20

3.6

3.5

3.4

3.3
0.0

0

1

2

3

Years since Randomization
No. at Risk
Atenolol
Losartan

303
304

287
293

282
279

268
267

ADVERSE EVENTS AND PARTICIPANT-REPORTED
SYMPTOMS

There was no significant difference between the
atenolol group and the losartan group in the overall rate of adverse events (408 events and 365 events,
respectively; P = 0.10) or serious adverse events
(40 events and 50 events, respectively; P = 0.31).
n engl j med 371;22

The rate of adverse events that were possibly or
probably related to the study drug was higher
with atenolol than with losartan (204 events vs.
163 events, P = 0.03), but the results did not differ
significantly when the analysis was restricted to
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—
—

No. of events

Event rate — % (95% CI)

Aortic-root surgery

—
—

No. of events

Event rate — % (95% CI)

Aortic dissection

No. of participants in the
analysis

2.3±0.5

—

—

—

—

—

0.00±0.00

—

—

—

—

—

294

280

280

293

293

304

—

—

—

—

—

0.01±0.19

2.3±0.5

1.1±1.1

2.0±0.4

1.8±1.4

3.4±0.7

4.4±1.5

—

—

—

—

—

0.32

0.42

0.08

0.79

0.29

0.96

0.14

P
Value

—

—

—

—

303

264

218

218

264

264

268

268

no. of
participants

3.4
(1.9–6.3)

10

0

0

—

0.02±0.36

2.4±0.4

0.5±0.8

2.0±0.4

0.9±1.2

3.5±0.7

3.7±1.3

Atenolol

—

—

—

—

305

263

236

236

262

262

267

267

no. of
participants

6.0
(3.8–9.4)

18

0.7
(0.2–2.7)

2

—

0.00±0.00

2.4±0.4

0.6±1.1

2.1±0.4

1.3±1.4

3.5±0.6

3.9±1.5

Losartan

At 3 Years

0.13

0.16

—

—

—

—

—

—

—

—

P
Value

—

—

—

—

—

0.005±0.003

0.039±0.004

−0.140±0.013

0.015±0.003

−0.279±0.018

0.069±0.004

−0.139±0.013

Atenolol

0.20

0.08

P
Value‡

—

—

—

—

—

0.001±0.003

0.044±0.004

−0.114±0.013

0.030±0.003

—

—

—

—

—

0.29

0.30

0.15

0.002

−0.175±0.018 <0.001

0.075±0.004

−0.107±0.013

Losartan

Annual Rate of Change†

of

—

263
294

Measurement — cm

Aortic-valve total regurgitant
jet area — mm2/m2 of
body-surface area

0.9±0.9

2.0±0.4

1.7±1.2

3.4±0.7

304

no. of
participants

Losartan

At Baseline

n e w e ng l a n d j o u r na l

Adverse clinical outcomes§

263

z Score

Ascending-aorta diameter

296

Measurement — cm

303

303

4.2±1.2

Atenolol
no. of
participants

z Score

Aortic-annulus diameter

Aortic-root diameter — cm

Other aortic measurements

Primary outcome: maximum
aortic-root-diameter
z score

Outcome

Table 2. Trial Outcomes According to Treatment Group.*

The

m e dic i n e

november 27, 2014

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on December 23, 2014. For personal use only. No other uses without permission.
Copyright © 2014 Massachusetts Medical Society. All rights reserved.

19

* Plus–minus values are means ±SD, except where otherwise noted. The z score was indexed to the body-surface area unless otherwise specified. CI denotes confidence interval.
† Data shown are estimated slopes of z scores in standard-deviation units per year ±SE and diameters in centimeters per year ±SE.
‡ P values are based on a linear regression mixed-effects model comparing slopes under compound symmetry, with adjustment for baseline.
§ Kaplan–Meier estimation was used to calculate all event rates. All P values are based on a log-rank test.
¶ The composite outcome was defined as the earliest event of aortic dissection, aortic-root surgery, or death.
‖ The group difference in the composite outcome at 3 years was 2.9 percentage points (95% CI, −0.6 to 6.4).

—

—

—

—
—

—
10

3.4
(1.9–6.3)
—

—
—

—
—

—
—

—
—
—
Event rate — % (95% CI)‖

—
—
No. of events¶

Composite outcome

6.4
(4.1–9.8)

0.10

—

—

1

—

—

—
—
—

—
0

0
—

—
—

—
—

—
—

—
—
—
Event rate — % (95% CI)

—
—
No. of events

Death

0.3
(0.0–2.4)

0.32

—

—
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serious adverse events (5 events and 2 events, respectively; P = 0.25). Further information about
adverse events and patient-reported symptoms is
provided in Table S9 in the Supplementary Appendix.

DISCUSSION
In this randomized trial comparing losartan
with atenolol in a large cohort of children and
young adults with Marfan’s syndrome and a dilated aortic root, we found no significant difference in the rate of aortic-root dilatation, indexed
to body-surface area, between the two treatment
groups over a 3-year period. The effects of treatment with these agents also did not differ significantly according to prespecified subgroups,
including younger versus older participants. We
did not find the expected advantage of ARB therapy over beta-blocker therapy. However, we found
a small but significant difference in favor of
atenolol with regard to the absolute diameter and
z score for the aortic annulus. This finding was
unexpected, without a clear physiological explanation.
The dose of the beta-blocker used in this
study was higher than that used in many other
studies. The dose of atenolol was adjusted for a
physiological effect, and the rate of change in
the aortic-root z score was not related to dose.
The dose of losartan reflected FDA recommendations at the time of protocol development and
was in a much narrower range than the dose of
atenolol. A higher dose of losartan or a different
ARB might have shown a greater effect on aortic
growth rate. We also found that diastolic blood
pressure was slightly but significantly lower in
the atenolol group than in the losartan group, an
effect that could reduce the aortic growth rate
and perhaps counter the effect of ARB-induced
suppression of TGF-β signaling in the losartan
group.
Although the rate of change in the aortic-root
z score did not differ significantly between the
two treatment groups, the aortic-root z score
decreased significantly over time in each group,
particularly in younger versus older participants,
which suggests that there may be value in beginning therapy relatively early in the disease
course. Without a placebo group, we are not able
to evaluate the magnitude of this benefit, although a previous study comparing beta-blocknejm.org
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Probability of Freedom from Aortic
Dissection, Surgery, and Death

1.0
1.00

0.8

Atenolol

0.98
0.96

0.6

0.94
0.4

Losartan

0.92

10 vs. 19 events
P=0.10 by log-rank test

0.90

0.2

0.00
0.0
0.0
0.0

0.5

0.5

1.0
1.0

1.5
1.5

2.0

2.5

2.0

3.0
2.5

3.0

281
280

166
149

Months since Randomization
No. at Risk
Atenolol
Losartan

303
305

297
300

293
298

292
295

290
286

Figure 3. Freedom from Adverse Clinical Outcomes, According to Treatment
Group.
The graph shows the estimated probability of freedom from aortic dissection, aortic-root surgery, and death (solid lines), according to treatment assignment, with 95% confidence intervals (dashed lines) for the pointwise
comparison. A total of 543 participants completed the 3-year follow-up visit
(mean follow-up, 3.0±0.1 years). The inset shows the same data on an enlarged y axis.

ers with placebo2 offers a basis for the conclusion that both agents are effective. The low rate
of bothersome participant-reported symptoms is
an important finding for both patients and their
medical providers because therapy can be selected
on the basis of individual patient and provider
preference.
There are methodologic differences between
our study and other, smaller studies that have
shown a benefit of losartan therapy. These include a direct comparison of losartan with a
beta-blocker in our study versus comparison of a
combination therapy with a beta-blocker alone
in other studies,22,23 similar blood pressures versus differential lowering in the treatment groups,23
the inclusion of both children and young adults
versus adults alone, and the exclusion of patients
with prior aortic surgery versus the inclusion of
such patients.23 In one study involving a small
number of participants, most of whom were
children, combined open-label losartan and betablocker therapy decreased the rate of aortic-root
dilatation more than did beta-blocker therapy
alone.22 The target doses of the beta-blocker
administered (maximum dose, 150 mg per day
in adults and 2 mg per kilogram per day in chil2070
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dren) were smaller than in our study, and the
exact doses achieved were not reported.22 In
contrast to the patient population in a retrospective study reported by Brooke et al.,11 which
showed a marked beneficial effect of an ARB
plus beta-blockers as compared with previous
therapy with beta-blockers alone, our study
population had a higher average age, the average
aortic-root z score was lower, and the betablocker dose was higher.11 Other trials of therapy in patients with Marfan’s syndrome are currently under way.24-28
This trial had several limitations. First, we
did not assess the effect of losartan therapy on
TGF-β. Second, the study results may not be
generalizable to persons with Marfan’s syndrome who have a body-surface area–adjusted
aortic-root z score of 3.0 or less. Third, the statistical power of the study was limited for the
detection of significant subgroup findings and
treatment differences for relatively low rates of
clinical events. Fourth, the primary outcome
was assessed by core laboratory personnel who
were unaware of the treatment assignments;
however, personnel supervising the study-drug
adjustments were aware of the treatment assignments, and some participants may have discovered their treatment assignment on the basis of
the appearance of the study drug. Finally, we
recognize the limitations of a surrogate end
point but believed a trial with a hard clinical end
point to be impractical, given the rarity of aortic
dissection or the need for aortic surgery in
young patients.
In conclusion, this trial involving children and
young adults with Marfan’s syndrome and aorticroot dilatation did not show the expected advantages of losartan over atenolol. The rate of
change in the aortic-root z score over the 3-year
period did not differ significantly between the
atenolol group and the losartan group.
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